Local IL‐10 level as a predictive factor in generalized aggressive periodontitis treatment response
Generalized aggressive periodontitis (GAgP) presents a reduced response to non‐surgical therapy. However, it is not clear if the initial clinical, microbiological or immunological characteristics are impacting the worse response to treatment. This study aimed to identify the predictive value of clin...
Gespeichert in:
| Veröffentlicht in: | Scandinavian journal of immunology 2019-12, Vol.90 (6), p.e12816-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 6 |
| container_start_page | e12816 |
| container_title | Scandinavian journal of immunology |
| container_volume | 90 |
| creator | Taiete, Tiago Monteiro, Mabelle F. Casati, Marcio Z. Vale, Hugo Felipe Ambosano, Glaucia M. B. Nociti, Francisco H. Sallum, Enilson A. Casarin, Renato C. V. |
| description | Generalized aggressive periodontitis (GAgP) presents a reduced response to non‐surgical therapy. However, it is not clear if the initial clinical, microbiological or immunological characteristics are impacting the worse response to treatment. This study aimed to identify the predictive value of clinical, microbiological and immunological patterns on the clinical response to therapy in GAgP patients. Twenty‐four GAgP patients were selected, and gingival crevicular fluid (GCF) and subgingival biofilm were collected. Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia levels were evaluated by qPCR, and IL‐1β and IL‐10 concentration by ELISA. Twelve patients were treated with SRP (scaling and root planning), and twelve with SRP plus 375 mg amoxicillin and 250 mg metronidazole (8/8 hours, 7 days) (SRP + AM). The clinical changes (Probing Pocket Depth [PPD] reduction and Clinical Attachment Level [CAL] gain) 6 months post‐treatment were correlated to the initial clinical, inflammatory and microbiological variables using stepwise logistic regression (α = 5%). CAL gain at 6 months was 1.16 ± 0.77 for SRP and 1.74 ± 0.57 mm for SRP + AM (P > .05). PPD reduction was 1.96 ± 0.82 for SRP and 2.45 ± 0.77 mm for SRP + AM (P .05). It can be concluded that the IL‐10 levels in GFC act as a predictor of clinical response to GAgP. Moreover, the intake of antimicrobials appears to overlap the influence of the inflammatory response on clinical response to treatment.
Clinical trial registration number: NCT03933501. |
| doi_str_mv | 10.1111/sji.12816 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2280523949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2319037339</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3886-17805bef077ccacab6cb49ff6cd0aa918d5194d4edd12fc1a986bde3f950d493</originalsourceid><addsrcrecordid>eNp10LtOwzAYhmELgWgpDNwAssQCQ1o7zsEeUcWhqBID3S3H_lO5SuNgp6AycQlcI1dCeoABCS8e_OiV9SF0TsmQdmcUFnZIY06zA9SnLEsjRjg7RH3CCIlEkqc9dBLCghDK4pwdox6jScI5y_sIpk6rCk-mXx-flOAKXqHCKmCFGw_G6ta-Ai6Vbp3HtsZzqMGryr6DwWo-9xDCBjTgrTOubm1rA249qHYJdYu798bVAU7RUamqAGf7e4Bmd7ez8UM0fbqfjG-mkWacZxHNOUkLKEmea620KjJdJKIsM22IUoJyk1KRmASMoXGpqRI8KwywUqTEJIIN0NUu23j3soLQyqUNGqpK1eBWQcZx14-Z2NLLP3ThVr7uPidjRgVhOWMbdb1T2rsQPJSy8Xap_FpSIjfTy256uZ2-sxf74qpYgvmVP1t3YLQDb7aC9f8l-fw42SW_Abq9j2k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2319037339</pqid></control><display><type>article</type><title>Local IL‐10 level as a predictive factor in generalized aggressive periodontitis treatment response</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Taiete, Tiago ; Monteiro, Mabelle F. ; Casati, Marcio Z. ; Vale, Hugo Felipe ; Ambosano, Glaucia M. B. ; Nociti, Francisco H. ; Sallum, Enilson A. ; Casarin, Renato C. V.</creator><creatorcontrib>Taiete, Tiago ; Monteiro, Mabelle F. ; Casati, Marcio Z. ; Vale, Hugo Felipe ; Ambosano, Glaucia M. B. ; Nociti, Francisco H. ; Sallum, Enilson A. ; Casarin, Renato C. V.</creatorcontrib><description>Generalized aggressive periodontitis (GAgP) presents a reduced response to non‐surgical therapy. However, it is not clear if the initial clinical, microbiological or immunological characteristics are impacting the worse response to treatment. This study aimed to identify the predictive value of clinical, microbiological and immunological patterns on the clinical response to therapy in GAgP patients. Twenty‐four GAgP patients were selected, and gingival crevicular fluid (GCF) and subgingival biofilm were collected. Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia levels were evaluated by qPCR, and IL‐1β and IL‐10 concentration by ELISA. Twelve patients were treated with SRP (scaling and root planning), and twelve with SRP plus 375 mg amoxicillin and 250 mg metronidazole (8/8 hours, 7 days) (SRP + AM). The clinical changes (Probing Pocket Depth [PPD] reduction and Clinical Attachment Level [CAL] gain) 6 months post‐treatment were correlated to the initial clinical, inflammatory and microbiological variables using stepwise logistic regression (α = 5%). CAL gain at 6 months was 1.16 ± 0.77 for SRP and 1.74 ± 0.57 mm for SRP + AM (P > .05). PPD reduction was 1.96 ± 0.82 for SRP and 2.45 ± 0.77 mm for SRP + AM (P < .05). In the SRP group, IL‐10 showed a predictive value for clinical response. The higher the IL‐10 concentration at baseline, the higher the reduction in PPD at 6 months (P = .01, r = .68). However, when antimicrobials were administered, no significant influence was detected (P > .05). It can be concluded that the IL‐10 levels in GFC act as a predictor of clinical response to GAgP. Moreover, the intake of antimicrobials appears to overlap the influence of the inflammatory response on clinical response to treatment.
Clinical trial registration number: NCT03933501.</description><identifier>ISSN: 0300-9475</identifier><identifier>EISSN: 1365-3083</identifier><identifier>DOI: 10.1111/sji.12816</identifier><identifier>PMID: 31448837</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aggressive Periodontitis - diagnosis ; Aggressive Periodontitis - etiology ; Aggressive Periodontitis - metabolism ; Aggressive Periodontitis - therapy ; Amoxicillin ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Antimicrobial agents ; Biofilms ; Biomarkers ; dental scaling ; Enzyme-linked immunosorbent assay ; Female ; Gingival Crevicular Fluid - metabolism ; Gingival Crevicular Fluid - microbiology ; Gum disease ; Humans ; Immunology ; Inflammation ; Inflammatory response ; Interleukin-10 - metabolism ; interleukin‐10 ; Male ; Metronidazole ; Patients ; Penicillin ; periodontal diseases ; Periodontitis ; Prognosis ; Root Planing - methods ; Treatment Outcome ; Young Adult</subject><ispartof>Scandinavian journal of immunology, 2019-12, Vol.90 (6), p.e12816-n/a</ispartof><rights>2019 The Scandinavian Foundation for Immunology</rights><rights>2019 The Scandinavian Foundation for Immunology.</rights><rights>Copyright © 2019 The Foundation for the Scandinavian Journal of Immunology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3886-17805bef077ccacab6cb49ff6cd0aa918d5194d4edd12fc1a986bde3f950d493</citedby><cites>FETCH-LOGICAL-c3886-17805bef077ccacab6cb49ff6cd0aa918d5194d4edd12fc1a986bde3f950d493</cites><orcidid>0000-0001-9333-4349</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fsji.12816$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fsji.12816$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31448837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taiete, Tiago</creatorcontrib><creatorcontrib>Monteiro, Mabelle F.</creatorcontrib><creatorcontrib>Casati, Marcio Z.</creatorcontrib><creatorcontrib>Vale, Hugo Felipe</creatorcontrib><creatorcontrib>Ambosano, Glaucia M. B.</creatorcontrib><creatorcontrib>Nociti, Francisco H.</creatorcontrib><creatorcontrib>Sallum, Enilson A.</creatorcontrib><creatorcontrib>Casarin, Renato C. V.</creatorcontrib><title>Local IL‐10 level as a predictive factor in generalized aggressive periodontitis treatment response</title><title>Scandinavian journal of immunology</title><addtitle>Scand J Immunol</addtitle><description>Generalized aggressive periodontitis (GAgP) presents a reduced response to non‐surgical therapy. However, it is not clear if the initial clinical, microbiological or immunological characteristics are impacting the worse response to treatment. This study aimed to identify the predictive value of clinical, microbiological and immunological patterns on the clinical response to therapy in GAgP patients. Twenty‐four GAgP patients were selected, and gingival crevicular fluid (GCF) and subgingival biofilm were collected. Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia levels were evaluated by qPCR, and IL‐1β and IL‐10 concentration by ELISA. Twelve patients were treated with SRP (scaling and root planning), and twelve with SRP plus 375 mg amoxicillin and 250 mg metronidazole (8/8 hours, 7 days) (SRP + AM). The clinical changes (Probing Pocket Depth [PPD] reduction and Clinical Attachment Level [CAL] gain) 6 months post‐treatment were correlated to the initial clinical, inflammatory and microbiological variables using stepwise logistic regression (α = 5%). CAL gain at 6 months was 1.16 ± 0.77 for SRP and 1.74 ± 0.57 mm for SRP + AM (P > .05). PPD reduction was 1.96 ± 0.82 for SRP and 2.45 ± 0.77 mm for SRP + AM (P < .05). In the SRP group, IL‐10 showed a predictive value for clinical response. The higher the IL‐10 concentration at baseline, the higher the reduction in PPD at 6 months (P = .01, r = .68). However, when antimicrobials were administered, no significant influence was detected (P > .05). It can be concluded that the IL‐10 levels in GFC act as a predictor of clinical response to GAgP. Moreover, the intake of antimicrobials appears to overlap the influence of the inflammatory response on clinical response to treatment.
Clinical trial registration number: NCT03933501.</description><subject>Adult</subject><subject>Aggressive Periodontitis - diagnosis</subject><subject>Aggressive Periodontitis - etiology</subject><subject>Aggressive Periodontitis - metabolism</subject><subject>Aggressive Periodontitis - therapy</subject><subject>Amoxicillin</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Biofilms</subject><subject>Biomarkers</subject><subject>dental scaling</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Female</subject><subject>Gingival Crevicular Fluid - metabolism</subject><subject>Gingival Crevicular Fluid - microbiology</subject><subject>Gum disease</subject><subject>Humans</subject><subject>Immunology</subject><subject>Inflammation</subject><subject>Inflammatory response</subject><subject>Interleukin-10 - metabolism</subject><subject>interleukin‐10</subject><subject>Male</subject><subject>Metronidazole</subject><subject>Patients</subject><subject>Penicillin</subject><subject>periodontal diseases</subject><subject>Periodontitis</subject><subject>Prognosis</subject><subject>Root Planing - methods</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0300-9475</issn><issn>1365-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10LtOwzAYhmELgWgpDNwAssQCQ1o7zsEeUcWhqBID3S3H_lO5SuNgp6AycQlcI1dCeoABCS8e_OiV9SF0TsmQdmcUFnZIY06zA9SnLEsjRjg7RH3CCIlEkqc9dBLCghDK4pwdox6jScI5y_sIpk6rCk-mXx-flOAKXqHCKmCFGw_G6ta-Ai6Vbp3HtsZzqMGryr6DwWo-9xDCBjTgrTOubm1rA249qHYJdYu798bVAU7RUamqAGf7e4Bmd7ez8UM0fbqfjG-mkWacZxHNOUkLKEmea620KjJdJKIsM22IUoJyk1KRmASMoXGpqRI8KwywUqTEJIIN0NUu23j3soLQyqUNGqpK1eBWQcZx14-Z2NLLP3ThVr7uPidjRgVhOWMbdb1T2rsQPJSy8Xap_FpSIjfTy256uZ2-sxf74qpYgvmVP1t3YLQDb7aC9f8l-fw42SW_Abq9j2k</recordid><startdate>201912</startdate><enddate>201912</enddate><creator>Taiete, Tiago</creator><creator>Monteiro, Mabelle F.</creator><creator>Casati, Marcio Z.</creator><creator>Vale, Hugo Felipe</creator><creator>Ambosano, Glaucia M. B.</creator><creator>Nociti, Francisco H.</creator><creator>Sallum, Enilson A.</creator><creator>Casarin, Renato C. V.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9333-4349</orcidid></search><sort><creationdate>201912</creationdate><title>Local IL‐10 level as a predictive factor in generalized aggressive periodontitis treatment response</title><author>Taiete, Tiago ; Monteiro, Mabelle F. ; Casati, Marcio Z. ; Vale, Hugo Felipe ; Ambosano, Glaucia M. B. ; Nociti, Francisco H. ; Sallum, Enilson A. ; Casarin, Renato C. V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3886-17805bef077ccacab6cb49ff6cd0aa918d5194d4edd12fc1a986bde3f950d493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aggressive Periodontitis - diagnosis</topic><topic>Aggressive Periodontitis - etiology</topic><topic>Aggressive Periodontitis - metabolism</topic><topic>Aggressive Periodontitis - therapy</topic><topic>Amoxicillin</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Biofilms</topic><topic>Biomarkers</topic><topic>dental scaling</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Female</topic><topic>Gingival Crevicular Fluid - metabolism</topic><topic>Gingival Crevicular Fluid - microbiology</topic><topic>Gum disease</topic><topic>Humans</topic><topic>Immunology</topic><topic>Inflammation</topic><topic>Inflammatory response</topic><topic>Interleukin-10 - metabolism</topic><topic>interleukin‐10</topic><topic>Male</topic><topic>Metronidazole</topic><topic>Patients</topic><topic>Penicillin</topic><topic>periodontal diseases</topic><topic>Periodontitis</topic><topic>Prognosis</topic><topic>Root Planing - methods</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taiete, Tiago</creatorcontrib><creatorcontrib>Monteiro, Mabelle F.</creatorcontrib><creatorcontrib>Casati, Marcio Z.</creatorcontrib><creatorcontrib>Vale, Hugo Felipe</creatorcontrib><creatorcontrib>Ambosano, Glaucia M. B.</creatorcontrib><creatorcontrib>Nociti, Francisco H.</creatorcontrib><creatorcontrib>Sallum, Enilson A.</creatorcontrib><creatorcontrib>Casarin, Renato C. V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Scandinavian journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taiete, Tiago</au><au>Monteiro, Mabelle F.</au><au>Casati, Marcio Z.</au><au>Vale, Hugo Felipe</au><au>Ambosano, Glaucia M. B.</au><au>Nociti, Francisco H.</au><au>Sallum, Enilson A.</au><au>Casarin, Renato C. V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Local IL‐10 level as a predictive factor in generalized aggressive periodontitis treatment response</atitle><jtitle>Scandinavian journal of immunology</jtitle><addtitle>Scand J Immunol</addtitle><date>2019-12</date><risdate>2019</risdate><volume>90</volume><issue>6</issue><spage>e12816</spage><epage>n/a</epage><pages>e12816-n/a</pages><issn>0300-9475</issn><eissn>1365-3083</eissn><abstract>Generalized aggressive periodontitis (GAgP) presents a reduced response to non‐surgical therapy. However, it is not clear if the initial clinical, microbiological or immunological characteristics are impacting the worse response to treatment. This study aimed to identify the predictive value of clinical, microbiological and immunological patterns on the clinical response to therapy in GAgP patients. Twenty‐four GAgP patients were selected, and gingival crevicular fluid (GCF) and subgingival biofilm were collected. Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia levels were evaluated by qPCR, and IL‐1β and IL‐10 concentration by ELISA. Twelve patients were treated with SRP (scaling and root planning), and twelve with SRP plus 375 mg amoxicillin and 250 mg metronidazole (8/8 hours, 7 days) (SRP + AM). The clinical changes (Probing Pocket Depth [PPD] reduction and Clinical Attachment Level [CAL] gain) 6 months post‐treatment were correlated to the initial clinical, inflammatory and microbiological variables using stepwise logistic regression (α = 5%). CAL gain at 6 months was 1.16 ± 0.77 for SRP and 1.74 ± 0.57 mm for SRP + AM (P > .05). PPD reduction was 1.96 ± 0.82 for SRP and 2.45 ± 0.77 mm for SRP + AM (P < .05). In the SRP group, IL‐10 showed a predictive value for clinical response. The higher the IL‐10 concentration at baseline, the higher the reduction in PPD at 6 months (P = .01, r = .68). However, when antimicrobials were administered, no significant influence was detected (P > .05). It can be concluded that the IL‐10 levels in GFC act as a predictor of clinical response to GAgP. Moreover, the intake of antimicrobials appears to overlap the influence of the inflammatory response on clinical response to treatment.
Clinical trial registration number: NCT03933501.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31448837</pmid><doi>10.1111/sji.12816</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9333-4349</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-9475 |
| ispartof | Scandinavian journal of immunology, 2019-12, Vol.90 (6), p.e12816-n/a |
| issn | 0300-9475 1365-3083 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2280523949 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aggressive Periodontitis - diagnosis Aggressive Periodontitis - etiology Aggressive Periodontitis - metabolism Aggressive Periodontitis - therapy Amoxicillin Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibiotics Antimicrobial agents Biofilms Biomarkers dental scaling Enzyme-linked immunosorbent assay Female Gingival Crevicular Fluid - metabolism Gingival Crevicular Fluid - microbiology Gum disease Humans Immunology Inflammation Inflammatory response Interleukin-10 - metabolism interleukin‐10 Male Metronidazole Patients Penicillin periodontal diseases Periodontitis Prognosis Root Planing - methods Treatment Outcome Young Adult |
| title | Local IL‐10 level as a predictive factor in generalized aggressive periodontitis treatment response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T08%3A33%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Local%20IL%E2%80%9010%20level%20as%20a%20predictive%20factor%20in%20generalized%20aggressive%20periodontitis%20treatment%20response&rft.jtitle=Scandinavian%20journal%20of%20immunology&rft.au=Taiete,%20Tiago&rft.date=2019-12&rft.volume=90&rft.issue=6&rft.spage=e12816&rft.epage=n/a&rft.pages=e12816-n/a&rft.issn=0300-9475&rft.eissn=1365-3083&rft_id=info:doi/10.1111/sji.12816&rft_dat=%3Cproquest_cross%3E2319037339%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2319037339&rft_id=info:pmid/31448837&rfr_iscdi=true |